^
    1year
    Antitumor activity of AX-0085, a novel AXL kinase inhibitor: Analysis of apoptotic cell death in triple-negative breast cancer cells. (ASCO 2023)
    Our results demonstrated that AX-0085 selectively blocks AXL activation which confers an effective therapeutic value in the treatment of TNBC. Currently, AX-0085 is undergoing non-clinical trials.
    PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BCL2 (B-cell CLL/lymphoma 2) • AXL (AXL Receptor Tyrosine Kinase) • CDK2 (Cyclin-dependent kinase 2) • CASP9 (Caspase 9)
    |
    PD-L1 expression • HER-2 expression • PGR expression • CDK2 expression
    |
    Cabometyx (cabozantinib tablet) • AX-0085